Pharmacokinetic and pharmacodynamic results of a 4-hr IV administration phase I study with EPC2407, a novel vascular disrupting agent This is an ASCO Meeting Abstract from the 2009 ASCO Annual Meeting ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results